myasthenia gravis, FcRn inhibitor, C5 inhibitor, efgartigimod, rozanolixizumab, eculizumab, ravulizumab, zilucoplan, combination therapy, refractory MG
Lung cancer, EGFR, Immune Checkpoint Inhibitor, macrophage, TIL, Cytokine